African Journal of Urology

, Volume 15, Issue 1, pp 1–6 | Cite as

The burden of disease associated with infection with human papillomavirus

Review Article
First Online:
Received:
Accepted:
  • 22 Downloads

Abstract

Human Papillomavirus is associated with a significant burden of disease globally, particularly with cancer of the cervix, for which persistent infection with high-risk types of HPV is necessary for the development of cervical cancer. Other cancers associated with HPV infection, particularly with HPV 16, include cancer of the vulva, vagina, penis, anus and some head and neck cancers. Globally approximately 600 000 cancers can be attributed to HPV infection. The advent of two commercially available vaccines had provided a new paradigm for the prevention of infection with HPV, particularly HPV infections associated with cancer.

Keywords

Human Papillomavirus (HPV) infection cancer 
This is a preview of subscription content, log in to check access.

Preview

Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.

References

  1. 1.
    Ferlay J, Bray F, Pisani P, Parkin DM. GLOBOCAN 2002: Cancer Incidence, mortality and prevalence worldwide. Lyon: IARC Press; 2004.Google Scholar
  2. 2.
    Walboomers JM, Jacobs MV, Manos MM, Bosch FX, Kummer JA, Shah KV, et al. Human papillomavirus is a necessary cause of invasive cervical cancer worldwide. J.Pathol. 1999; Sep;189(1):12–19.PubMedCrossRefGoogle Scholar
  3. 3.
    Munoz N, Bosch FX, de Sanjose S, Herrero R, Castellsague X, Shah KV, et al. Epidemiologic classification of human papillomavirus types associated with cervical cancer. N.Engl.J.Med. 2003; Feb 6;348(6):518–527.PubMedCrossRefGoogle Scholar
  4. 4.
    Clifford GM, Smith JS, Plummer M, Munoz N, Franceschi S. Human papillomavirus types in invasive cervical cancer worldwide: A meta-analysis. Br.J.Cancer. 2003; Jan 13;88(1):63–73.PubMedCrossRefGoogle Scholar
  5. 5.
    Wright TC, Kurman RJ, Ferenczy A. Precancerous lesions of the cervix. In: Kurman RJ, editor. Blaustein’s pathology of the female genital tract. 5th ed.: New York: Springer-Verlag; 2002. p. 1376.Google Scholar
  6. 6.
    Harper DM, Franco EL, Wheeler C, Ferris DG, Jenkins D, Schuind A, et al. Efficacy of a bivalent L1 virus-like particle vaccine in prevention of infection with human papillomavirus types 16 and 18 in young women: A randomised controlled trial. Lancet. 2004; Nov 13–19;364(9447):1757–1765.PubMedCrossRefGoogle Scholar
  7. 7.
    Harper DM, Franco EL, Wheeler CM, Moscicki AB, Romanowski B, Roteli Martins CM, et al. Sustained efficacy up to 4.5 years of a bivalent L1 virus-like particle vaccine against human papillomavirus types 16 and 18: Follow-up from a randomised control trial. Lancet. 2006; Apr 15;367(9518):1247–1255.PubMedCrossRefGoogle Scholar
  8. 8.
    Koutsky LA, Ault KA, Wheeler CM, Brown DR, Barr E, Alvarez FB, et al. A controlled trial of a human papillomavirus type 16 vaccine. N.Engl.J.Med. 2002; Nov 21;347(21):1645–1651.PubMedCrossRefGoogle Scholar
  9. 9.
    Mao C, Koutsky LA, Ault KA, Wheeler CM, Brown DR, Wiley DJ, et al. Efficacy of human papillomavirus-16 vaccine to prevent cervical intraepithelial neoplasia: A randomized controlled trial. Obstet.Gynecol. 2006; Jan;107(1):18–27.PubMedCrossRefGoogle Scholar
  10. 10.
    Villa LL, Costa RL, Petta CA, Andrade RP, Ault KA, Giuliano AR, et al. Prophylactic quadrivalent human papillomavirus (types 6, 11, 16 and 18) L1 virus-like particle vaccine in young women: A randomised double-blind placebo-controlled multicentre phase II efficacy trial. Lancet Oncol. 2005; May;6(5):271–278.PubMedCrossRefGoogle Scholar
  11. 11.
    Villa LL, Ault KA, Giuliano AR, Costa RL, Petta CA, Andrade RP, et al. Immunologic responses following administration of a vaccine targeting human papillomavirus Types 6, 11, 16 and 18. Vaccine. 2006; Jul 7;24(27–28):5571–5583.PubMedCrossRefGoogle Scholar
  12. 12.
    The Future II Study Group, Quadrivalent vaccine against human papillomavirus to prevent high-grade cervical lesions. N.Engl.J.Med. 2007; May 10;356(19):1915–1927.CrossRefGoogle Scholar
  13. 13.
    Goldie SJ, Kohli M, Grima D, Weinstein MC, Wright TC, Bosch FX, et al. Projected clinical benefits and cost-effectiveness of a human papillomavirus 16/18 vaccine. J.Natl.Cancer Inst. 2004; Apr 21;96(8):604–615.PubMedCrossRefGoogle Scholar
  14. 14.
    Summary Chapter: IARC Working Group on Cervical Cancer Screening. In: Hakama M, Miller AB, Day NE, editors. Screening for cancer of the uterine cervix. Lyon: International Agency for Research on Cancer; 1986, pp 133–142.Google Scholar
  15. 15.
    Sankaranarayanan R, Gaffikin L, Jacob M, Sellors J, Robles S. A critical assessment of screening methods for cervical neoplasia. Int.J.Gynaecol.Obstet. 2005; May;89Suppl 2:S4–S12.PubMedCrossRefGoogle Scholar
  16. 16.
    Parkin DM, Whelan SL, Ferlay J, Teppo L, Thomas DB. Cancer incidence in five continents. Lyon, France: IARC Scientific Publications; 2002.Google Scholar
  17. 17.
    Maden C, Sherman KJ, Beckmann AM, Hislop TG, Teh CZ, Ashley RL, et al. History of circumcision, medical conditions and sexual activity and risk of penile cancer. J.Natl.Cancer Inst. 1993; Jan 6;85(1):19–24.PubMedCrossRefGoogle Scholar
  18. 18.
    Heideman DA, Waterboer T, Pawlita M, Delis van Diemen P, Nindl I, Leijte JA, et al. Human papillomavirus-16 is the predominant type etiologically involved in penile squamous cell carcinoma. J.Clin.Oncol. 2007; Oct 10;25(29):4550–4556.PubMedCrossRefGoogle Scholar
  19. 19.
    Backes DM, Kurman RJ, Pimenta JM, Smith JS. Systemic review of human papillomavirus prevalence in invasive penile cancer. Cancer Causes Control;DOI 10.1007/s10552-008-9276-9.Google Scholar
  20. 20.
    Skapa P, Zamecnik J, Hamsikova E, Salakova M, Smahelova J, Jandova K, et al. Human papillomavirus (HPV) profiles of vulvar lesions: Possible implications for the classification of vulvar squamous cell carcinoma precursors and for the efficacy of prophylactic HPV vaccination. Am.J.Surg.Pathol. 2007; Dec;31(12):1834–1843.PubMedCrossRefGoogle Scholar
  21. 21.
    Giuliano AR, Tortolero Luna G, Ferrer E, Burchell AN, de Sanjose S, Kjaer SK, et al. Epidemiology of human papillomavirus infection in men, cancers other than cervical and benign conditions. Vaccine. 2008; Aug 19;26Suppl 10:K17–28.PubMedCrossRefGoogle Scholar
  22. 22.
    Daling JR, Madeleine MM, Schwartz SM, Shera KA, Carter JJ, McKnight B, et al. A population-based study of squamous cell vaginal cancer: HPV and cofactors. Gynecol.Oncol. 2002; Feb;84(2):263–270.PubMedCrossRefGoogle Scholar
  23. 23.
    Carter JJ, Madeleine MM, Shera K, Schwartz SM, Cushing Haugen KL, Wipf GC, et al. Human papillomavirus 16 and 18 L1 serology compared across anogenital cancer sites. Cancer Res. 2001; Mar 1;61(5):1934–1940.PubMedGoogle Scholar
  24. 24.
    IARC Human Papillomavirus. IARC Monographs on the Evaluation of Carcinogenic Risk to Humans. Lyon: IARC Press, 2007, 90:215–222.Google Scholar
  25. 25.
    Kreimer AR, Clifford GM, Boyle P, Franceschi S. Human papillomavirus types in head and neck squamous cell carcinomas worldwide: A systematic review. Cancer Epidemiol.Biomarkers Prev. 2005; Feb;14(2):467–475.PubMedCrossRefGoogle Scholar
  26. 26.
    Fenton KA, Korovessis C, Johnson AM, McCadden A, McManus S, Wellings K, et al. Sexual behaviour in Britain: Reported sexually transmitted infections and prevalent genital Chlamydia trachomatis infection. Lancet. 2001; Dec 1;358(9296):1851–1854.PubMedCrossRefGoogle Scholar
  27. 27.
    Kjaer SK, Tran TN, Sparen P, Tryggvadottir L, Munk C, Dasbach E, et al. The burden of genital warts: A study of nearly 70,000 women from the general female population in the 4 Nordic countries. J.Infect.Dis. 2007; Nov 15;196(10):1447–1454.PubMedCrossRefGoogle Scholar
  28. 28.
    Parkin DM. The global health burden of infection- associated cancers in the year 2002. Int.J.Cancer. 2006; Jun 15;118(12):3030–3044PubMedCrossRefGoogle Scholar

Copyright information

© PAUSA and Springer Verlag France 2009

Authors and Affiliations

  1. 1.Gynecology Oncology Unit, Department of Obstetrics & GynaecologyUniversity of Cape Town/Groote Schuur HospitalCape TownSouth Africa

Personalised recommendations